Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Pioglitazone 30 mg Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Diabetes mellitus Type 2 De-escalation treatment (DET); Drug
Lead sponsor: Sciema UG; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Pioglitazone; Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Diabetes Mellitus, Type 2
Interventions: linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 2,122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 13
States / cities: Chula Vista, California • Spring Valley, California • Walnut Creek, California + 10 more

Conditions: Diabetes Mellitus
Interventions: Alogliptin and pioglitazone, Pioglitazone; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more

Conditions: Bipolar Disorder, Insulin Resistance
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Gastroparesis
Interventions: Pioglitazone 30 mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Polycystic Ovary Syndrome
Interventions: pioglitazone, metformin, placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Type 2 Diabetes Mellitus
Interventions: Pioglitazone; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: pioglitazone; Drug
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obese, Metabolic Syndrome
Interventions: Mirabegron, Pioglitazone, Mirabegron and Pioglitazone; Drug
Lead sponsor: Philip Kern; Other
Eligibility: 35 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Hepatitis
Interventions: Actos (Pioglitazone); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, metformin, sitagliptin, pioglitazone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 18
States / cities: Buena Park, California • Los Angeles, California • Valencia, California + 15 more

Conditions: Metabolic Syndrome
Interventions: Pioglitazone, Placebo, Niacin ER, Aspirin; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis
Interventions: pioglitazone; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions: Pioglitazone study drug, Placebo, Pioglitazone Open Label; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C
Interventions: Pioglitazone, Prednisone; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes Mellitus, Type 2
Interventions: pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo; Drug · Dietary Supplement
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 1,332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 23
States / cities: Long Beach, California • Los Angeles, California • Northridge, California + 19 more

Conditions: Uric Acid Kidney Stone Disease
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 99 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus
Interventions: Alogliptin, Pioglitazone, Metformin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Lake Havasu City, Arizona + 83 more

Conditions: Type 2 Diabetes
Interventions: Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 70 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 14
States / cities: La Jolla, California • Norwalk, California • Miami, Florida + 10 more

Conditions: Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
Interventions: Pioglitazone, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions: Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 40 Years to 79 Years
Enrollment: 10,251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 6
States / cities: Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more

Conditions: Insulin Resistance, Prostate Cancer
Interventions: Pioglitazone 30 Mg Oral Tablet, Pioglitazone placebo tablet; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 85 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment
Interventions: Pioglitazone, Life style diet group, Placebo; Drug · Behavioral · Other
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Pioglitazone for the Treatment of Bipolar Depression

Pioglitazone for Idiopathic Gastroparesis

Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)

Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?

Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes

Brown Fat Activation Study

Treating Nonalcoholic Steatohepatitis With Pioglitazone

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease

University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)

Study the Relationship Between Obesity and Hepatitis C Replication

Thiazolidinedione Intervention With Vitamin D Evaluation

Pathophysiology of Uric Acid Nephrolithiasis

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

Quantifying Hepatic Mitochondrial Fluxes in Humans

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Insulin Resistance Following ADT for Prostate CA

Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia